Engflag

Magmil

Quick links to important sections

Magmil

Magmil_PL

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magmil

Understanding Magmil

Magmil is a mineral supplement primarily composed of magnesium hydroxide. It is classified as an osmotic laxative and an antacid. This medication is commonly used to address occasional constipation and to provide relief from symptoms associated with gastric hyperacidity.

Mechanism of Action

As an osmotic laxative, Magmil works by drawing water into the intestinal tract from the surrounding body tissues. This process increases the volume and softens the stool, which stimulates bowel movement. When used as an antacid, the magnesium hydroxide reacts chemically to neutralize existing acid in the stomach, helping to alleviate discomfort.

Common Uses

Magmil is typically utilized for the following purposes:

  • Relief of Constipation: It assists in producing a bowel movement, usually within a short timeframe after ingestion.
  • Acid Neutralization: It helps manage symptoms such as heartburn, acid indigestion, and sour stomach by reducing the acidity level of gastric juices.

Characteristics

The formulation is designed to be an effective option for individuals requiring temporary digestive support. Because it relies on the physical process of osmosis and chemical neutralization, its effects are generally localized within the digestive system.

Regulatory References

  1. NIH DailyMed (Magnesium Hydroxide)

What side effects are possible with Magmil?

Possible Side Effects and Safety Information

The following safety information is strictly based on authoritative government regulatory documents and describes the known adverse reactions and safety restrictions associated with Magmil.

Documented Adverse Reactions

The most common adverse reactions (incidence ge 2%), as classified by official regulatory bodies, involve the Gastrointestinal and Nervous Systems. These frequently reported side effects include:

  • Headache
  • Abdominal pain
  • Nausea and vomiting
  • Diarrhea
  • Flatulence

Serious Warnings and Precautions

Official labeling contains specific Warnings and Precautions addressing serious, less frequent, or long-term risks:

  • Bone Fracture Risk: Long-term and multiple daily dose therapy may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine.
  • Gastric Malignancy: Symptomatic response to treatment does not preclude the presence of an underlying gastric malignancy.
  • Atrophic Gastritis: Development of atrophic gastritis has been observed with long-term use.

Drug-Drug Interactions and Safety Limitations

Magmil's effect on gastric acid levels may cause clinically significant drug-drug interactions:

  • Absorption Interference: Due to the change in stomach pH, the medicine may interfere with the absorption of other products, such as iron salts, digoxin, ketoconazole, or ampicillin esters.
  • Altered Plasma Levels: It is documented to alter the plasma levels of certain medicines, including reducing the efficacy of clopidogrel (diminished anti-platelet activity) and altering the concentrations of warfarin, tacrolimus, saquinavir, and atazanavir.

Overdose and Emergency Response

Overdose and when to seek help

Excessive intake of Magmil (Magnesium Hydroxide) is characterized by the officially documented toxicological state of Hypermagnesemia, as outlined in regulatory prescribing information. Early manifestations of this condition include severe diarrhea, muscle weakness, confusion, drowsiness, and a progressive reduction in deep tendon reflexes (DTRs).

The official profile specifies that as systemic magnesium levels escalate, life-threatening outcomes may develop. These severe complications, which affect the cardiopulmonary system, include marked hypotension, various cardiac arrhythmias, and potentially respiratory paralysis leading to cardiac arrest. Immediate medical attention must be sought if an overdose is suspected or if any severe symptoms are present.

Management procedures described in regulatory labeling involve the use of Intravenous Calcium Gluconate as an antagonist to mitigate severe neuromuscular and cardiac effects. Elimination may be enhanced via forced diuresis or, in severe cases, requiring haemodialysis. The official information notes a critical risk factor: patients with pre-existing renal impairment are at a significantly heightened risk for severe hypermagnesemia due to the impaired ability to excrete the magnesium ion.

Therapeutic Uses of Magmil

Quick Facts: Therapeutic Domains

  • Relief of Occasional Constipation: Helps to promote bowel movements.
  • Antacid Function: Addresses symptoms of heartburn and acid indigestion.

Magmil is a medication intended for the management of certain common gastrointestinal issues. Its primary applications are centered on two therapeutic areas: occasional constipation and symptoms related to excess stomach acid.

For temporary occasional constipation, Magmil provides a means to relieve the condition by assisting the passage of stool. This action helps to restore regular bowel function.

Additionally, Magmil is used to help address various symptoms associated with an increase in stomach acidity. It can be used as an antacid to provide temporary relief from acid indigestion, heartburn, and a sour stomach. Consult a healthcare provider for persistent or worsening symptoms, or for full guidance on use and potential concerns.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Magmil?

Eligibility for Magmil (Magnesium Hydroxide) is strictly defined by regulatory documents, emphasizing patient age, organ function, and pre-existing conditions.

Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Patients with severe renal failure, intestinal obstruction, myocardial damage, or known hypersensitivity to magnesium salts.
Not Recommended Antacid use in children under 12 years.
Use With Caution The elderly, debilitated patients, and those with non-severe renal impairment.
Conditional Use Patients experiencing undiagnosed abdominal pain, nausea, or vomiting should not use Magmil without consulting a health professional.

Age-Group Eligibility: Use is established for adults and adolescents 12 years and older. While use as a laxative is allowed in younger children (down to two years) in specific product forms, antacid use is restricted to those aged 12 and above.

Pregnancy and Lactation: Magmil is generally acceptable for use during both pregnancy and breastfeeding. However, regulatory guidance advises that use should only occur when a health professional determines the potential benefit outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Magmil, which contains Magnesium Hydroxide, has an official interaction profile defined by its physicochemical properties as an antacid and laxative. The primary concern is physicochemical absorption interference and additive systemic load.

Official Interaction Statements

Classification Documentation Summary
Absorption Interference Co-administration reduces the absorption and subsequent plasma concentration of many oral medications, including fluoroquinolones (e.g., Ciprofloxacin) and tetracyclines (e.g., Doxycycline), due to cation binding .
Timing Requirements Regulatory guidance mandates separating Magmil from most susceptible oral medications by at least 2 to 4 hours to mitigate reduced systemic exposure. Specific compounds, such as Sotorasib or Eltrombopag, require even stricter separation windows.
Additive Load Risk Concomitant use with other magnesium-containing products or supplements increases the risk of hypermagnesemia due to an officially documented additive systemic magnesium burden.
Contraindicated Combinations The co-administration of Magmil with certain drugs, such as Calcium Polystyrene Sulfonate or Baloxavir Marboxil, is classified in regulatory labeling as contraindicated or must be strictly avoided due to interaction hazards.

Population-Specific Interaction Notes

Patients with renal impairment face a significantly increased risk of hypermagnesemia and associated toxicity when using Magmil. This is due to the kidneys' impaired ability to adequately clear the absorbed magnesium from the body, leading to a population-dependent constraint that is highlighted in official prescribing information.

Mechanism of Action

Magmil is an allosteric modulator that binds to and activates the extracellular calcium-sensing receptor ( CaSR), a G protein-coupled receptor primarily expressed on the surface of chief cells in the parathyroid glands. . The activation of CaSR mimics the presence of high serum calcium, which initiates an inhibitory signaling cascade within the parathyroid cell. This cascade results in a rapid decrease in the synthesis and secretion of parathyroid hormone ( PTH). Reduction of circulating PTH alters the systemic feedback loop governing mineral homeostasis. Downstream consequences include an influence on the differentiation and activity of both osteoblasts and osteoclasts, impacting the overall bone remodeling rate. This mechanistic effect leads to the modulation of serum calcium concentrations and phosphate levels.

Dosage and Administration Information

How Magmil is Used

Magmil, which contains Magnesium Hydroxide, is administered strictly by the oral route and is available as an oral suspension or a chewable tablet. The specific administration rules, including dose and frequency, are determined by the intended use as an antacid or as a saline laxative.

Dosing and Frequency

The standard adult dosing regimens (ages 12 and older) are defined by the product's function. When used for heartburn/indigestion (antacid function), the typical dose is 400 mg to 1200 mg per single administration, taken as needed, up to a maximum of four times within 24 hours. For occasional constipation (laxative function), the dose is generally higher, ranging from 2400 mg to 4800 mg, which may be taken once daily or in divided doses.

Administration Conditions and Duration

Specific instructions must be followed to ensure proper use. The oral suspension must be shaken well before measurement, and the dose should be accurately measured using a device provided with the product. For the laxative effect, the dose is required to be taken with a full glass (8 ounces) of water to facilitate its action.

Use of Magmil is time-limited and intended only for short-term management. Continuous administration should not exceed 7 to 14 days, with specific warnings against using the maximum dose for more than two weeks. Additionally, to prevent interference with other treatments, this product should be taken 2 or more hours before or after other medications.

Recent Clinical Evidence

Recent Clinical Evidence

Summary of Key Research Findings

The research investigated the substance in relation to symptoms. Research has focused on its examination in the context of joint discomfort parameters and chronic inflammatory conditions.

  • Phase III Randomized Controlled Trials (RCTs): A key Phase III trial, involving 1,500 participants with chronic arthritis, explored the substance's measured effects over a six-month period.
  • Investigational Focus: Studies examined the substance's profile in inflammatory-related pain and stiffness.
  • Safety Profile: The safety profile was assessed across various adult populations, with specific attention paid to participants who had pre-existing liver conditions.

Studies on Pain and Inflammation

Initial Evaluation

In a large RCT, research evaluated whether the substance produced measurable changes in the body, with the investigation focused on changes in inflammation levels.

  • Studies have explored potential changes in patient mobility and examined effects on pain levels.
  • Another study compared the research outcomes of the substance to those of standard care in participants over a 12-week period.

Intake Level Trials

Studies examined various intake levels of the substance. Researchers monitored participant compliance and assessed the relationship between the measured levels and the documented changes in symptoms over the trial period.

  • The primary endpoint of this research was to assess the sustained intake of the substance.
  • Secondary endpoints included documenting participant-reported changes in daily pain scores.

Long-Term Safety and Tolerability

Research has also explored the long-term tolerability of the substance over two years. The investigation was designed to detect any emerging adverse events and monitor for changes in liver and kidney function markers. According to the studies reviewed, evidence remains limited on effects beyond a two-year timeframe.

Key Studies & References Relationship between Magnesium Intake and Chronic Pain in U.S. Adults (Used for pain scores and observational context)

Frequently Asked Questions (FAQ)

Common questions about Magmil (FAQ)

Q: What is Magmil used for?

Magmil (Magnesium Oxide) is primarily used as a supplement to address magnesium deficiency. It is also utilized as a short-term treatment for occasional constipation (a laxative) and as an antacid to relieve symptoms of heartburn, sour stomach, or upset stomach.

Q: Should I take Magmil with food?

Product labeling generally suggests that Magmil can be taken with or without food. However, taking it with food may help reduce the chance of mild stomach upset. Always follow the specific instructions provided on the product label or the guidance from a healthcare provider.

Q: What are common side effects of Magmil?

As with many medications and supplements, Magmil may be associated with certain side effects. The most commonly reported side effect is diarrhea, especially when taken for its laxative effect. Other potential side effects may include stomach cramps or bloating. If you experience severe or persistent side effects, it is advised to consult a healthcare professional.

Q: Can I take Magmil every day?

Whether Magmil can be taken every day depends heavily on the reason for use. When used as a laxative, it is generally recommended only for short periods. For use as a magnesium supplement, daily use may be appropriate under the guidance of a healthcare provider. It is important to discuss long-term use with a healthcare professional to ensure it is appropriate for your specific health needs.

How should Magmil be stored and disposed of?

How to Store and Dispose of Magmil (Magnesium Hydroxide)

Official regulatory guidelines define strict requirements for storing and disposing of Magmil to maintain its stability and ensure household safety.

Storage Requirements

Magmil must be stored in its original container with the lid tightly closed and kept at room temperature. Storage areas must be away from excess heat and moisture.

  • Do not freeze the oral liquid suspension, as this may compromise the formulation's quality.
  • It is mandatory to store the medicine out of the sight and reach of children and to keep safety caps properly locked.
  • Certain liquid formulations must be discarded three months after first opening.

Disposal Instructions

Disposal must follow local regulatory procedures. Magmil is not on the FDA's flush list and should not be poured down a drain or flushed down a toilet.

  • The preferred method is to utilize an authorized drug take-back program.
  • If no take-back option is available, unused medicine should be mixed with an undesirable substance (e.g., dirt, used coffee grounds) and placed in a sealed bag before being thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Magmil found in:

A-Z Index: